Literature DB >> 2780262

Primary survival and prosthetic fitting of lower limb amputees.

T Pohjolainen1, H Alaranta, J Wikström.   

Abstract

During the period 1984-1985 amputation of the lower limb at a level potentially requiring a prosthesis was performed on 577 patients in 16 operative units. The mean age was 75.7 years for females and 68.1 for males. The most common site of the amputation was above the knee (49.9%). The majority of amputations (93.8%) were performed for vascular diseases and diabetes. Survival figures showed that 25.5% of amputees died within 2 months of amputation, 60.7% were alive after one year and 43.2% after two years. Out of a total of 577 patients, 26.9% were fitted with a prosthesis. Out of below-knee and above-knee amputees surviving over 2 months, 61.5% and 27.2% respectively were fitted with a prosthesis. There were markedly fewer prosthetic fittings in the over-60 age group. Diabetic patients of both sexes were fitted with a prosthesis more often than arterio-sclerotic patients. Among tumour patients 82.4% received a prosthesis. In the study area more emphasis must be put on the concept of preserving the knee joint and preoperative assessment of vascular patients for selection of amputation level. Every effort must be made to avoid delay in the postoperative mobilization and rehabilitation. Prosthetic fitting of amputees could be improved by better liaison between surgical unit and specialized rehabilitation unit and by closer team approach of amputee care.

Entities:  

Mesh:

Year:  1989        PMID: 2780262     DOI: 10.3109/03093648909078214

Source DB:  PubMed          Journal:  Prosthet Orthot Int        ISSN: 0309-3646            Impact factor:   1.895


  10 in total

1.  A multidisciplinary approach and surgical tips in major amputations of diabetic patients.

Authors:  Marco Rosati; Michele Lisanti; Alessandro Baluganti; Lorenzo Andreani; Loredana Rizzo; Alberto Piaggesi
Journal:  Musculoskelet Surg       Date:  2012-07-31

2.  Risk factors associated with mortality in veteran population following transtibial or transfemoral amputation.

Authors:  Barbara Bates; Margaret G Stineman; Dean M Reker; Jibby E Kurichi; Pui L Kwong
Journal:  J Rehabil Res Dev       Date:  2006 Nov-Dec

3.  Amputation for occlusive arterial disease. A prospective multicentre study of 177 amputees.

Authors:  M Eneroth; B M Persson
Journal:  Int Orthop       Date:  1992       Impact factor: 3.075

4.  Clinical factors associated with prescription of a prosthetic limb in elderly veterans.

Authors:  Jibby E Kurichi; Pui L Kwong; Dean M Reker; Barbara E Bates; Clifford R Marshall; Margaret G Stineman
Journal:  J Am Geriatr Soc       Date:  2007-06       Impact factor: 5.562

5.  Revisiting risks associated with mortality following initial transtibial or transfemoral amputation.

Authors:  Barbara E Bates; Dawei Xie; Jibby E Kurichi; Diane Cowper Ripley; Pui L Kwong; Margaret G Stineman
Journal:  J Rehabil Res Dev       Date:  2012

6.  Survival analysis in amputees based on physical independence grade achievement.

Authors:  Margaret G Stineman; Jibby E Kurichi; Pui L Kwong; Greg Maislin; Dean M Reker; W Bruce Vogel; Janet A Prvu-Bettger; Douglas E Bidelspach; Barbara E Bates
Journal:  Arch Surg       Date:  2009-06

7.  Use of prostheses in lower limb amputee patients due to peripheral arterial disease.

Authors:  Therezinha Rosane Chamlian
Journal:  Einstein (Sao Paulo)       Date:  2014 Oct-Dec

Review 8.  Understanding Low Back Pain in Traumatic Lower Limb Amputees: A Systematic Review.

Authors:  Biranavan Sivapuratharasu; Anthony M J Bull; Alison H McGregor
Journal:  Arch Rehabil Res Clin Transl       Date:  2019-06-25

9.  Maximal Walking Distance in Persons with a Lower Limb Amputation.

Authors:  Cheriel J Hofstad; Kim T J Bongers; Mark Didden; René F van Ee; Noël L W Keijsers
Journal:  Sensors (Basel)       Date:  2020-11-26       Impact factor: 3.576

10.  Cost of managing complications resulting from type 2 diabetes mellitus in Canada.

Authors:  Judith A O'Brien; Amanda R Patrick; J Jaime Caro
Journal:  BMC Health Serv Res       Date:  2003-03-21       Impact factor: 2.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.